Professor Chris Liddle
Professor of Clinical Pharmacology & Hepatology
C24 - Westmead Hospital
Over the past decade Chris' main area of research has been in the functional genomics of human drug metabolism and adaptive responses to toxic xenobiotic (foreign) and endobiotic (endogenous) chemical compounds. An extension of this work is to understand how the liver protects itself from toxic damage, as occurs in liver diseases where the flow of bile is obstructed (cholestatic liver diseases). More recent work has focused on the role of nuclear hormone receptors in hepatic fibrogenesis, particularly the role of the Vitamin D Receptor as a therapeutic target to prevent progression to cirrhosis in patients with chronic liver disease. These research projects have resulted in three patent families, two of which have been commercialized, as well as many highly cited publications. Chris also has interests in advanced information technology systems in the fields of biomedical research and clinical medicine. He is presently working on the bioinformatics of Next-Gen DNA sequencing technologies applied to gene regulation (e.g.; ChIP-Seq and RNA-Seq) and has contributed to very high impact publications, including recent papers in in the journals Nature, Nature Medicine, Cell and Molecular Cell.
Clinical Pharmacology, Drug Metabolism, Liver Diseases, Bioinformatics
Current national competitive grants*
How do the Vitamin D Receptor activation genes CYP27B1 and CYP24A1 alter susceptibility to autoimmune diseases?
Booth D, Batten M, Stewart G, Liddle C
NHMRC Project Grant ($504,508 over 3 years)
A Multi-site study of Tamoxifen dose escalation study in breast cancer patients with CYP2D6 polymorphisms (TADE study)
Gurney H, Balleine R, Wilcken N, Liddle C
NHMRC Project Grants ($329,901 over 3 years)
* Grants administered through the University of Sydney
United States. (Genentec Inc., San Francisco, CA.) Collaboration, Hepatic Gene Regulation.
United States. (Deltagen Inc., San Mateo, CA.) IP Licensee, Tools for Drug Screening..
Netherlands. (Academic Medical Center, Amsterdam.) Collaboration, Pharmacogenomics of Cancer Chemotherapy.
Belgium. (Catholic University, Leuven.) Collaboration, Bile Acids in Critically Ill Patients.
United States. (Salk Institute for Biological Studies, La Jolla, CA.) Adjunct Professor (appointed 2010).
Netherlands. (University Medical Center, Groningen.) Collaboration, Hepatocyte Transporters..